Results 91 to 100 of about 7,378 (198)

Stability Enhancement of Mesalamine Delayed-Release Tablets 1.2g [PDF]

Mesalamine (5-aminosalicylic acid) is widely used for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis. Commercially available mesalamine delayed-release formulations, such as LIALDA (Mesalamine) Delayed-Release Tablets 1.2
Anonymous,
core   +1 more source

Endoscopic and clinicopathological features of segmental colitis associated with diverticulosis

DEN Open
Objectives Segmental colitis associated with diverticulosis (SCAD) has close endoscopic and pathological similarities to ulcerative colitis (UC) and Crohn's disease. Clinical data on SCAD are limited in Japan.
Kazuhiko Obata, Kan Uchiyama, Ryuzo Murai   +2 more
doaj   +1 more source

Mesalamine: Safe at first look [PDF]

Inflammatory Bowel Diseases, 1999
L J, Saubermann, J L, Wolf
openaire   +2 more sources

Enhanced Bioavailability and Targeted Delivery of Mesalamine for Crohn’s Disease Using Microemulsion Formulations

This study evaluates mesalamine-loaded microemulsions designed to enhance drug bioavailability and site-specific delivery in the gastrointestinal (GI) tract, targeting the treatment of Crohn\u27s disease.
Subham Mandal, Km. Bhumika, Mukesh Kumar, Suraj Mandal, Iram Jahan, Shadab Ali   +5 more
core   +1 more source

Idiopathic Intracranial Hypertension Related to Chronic Use of Mesalamine: A Case Report and Literature Review

, 2019
Idiopathic intracranial hypertension (IIH) is commonly seen related to iatrogenic causes such as excess retinol, tetracyclines, and amiodarone. We report a case of IIH likely related to mesalamine use.
Mehta, Dev, Yacoub, Hussam A., MD, El-Hunjul, Mohammed   +2 more
core   +1 more source

Eosinophilic pleural effusion due to mesalamine. Report of a rare occurence

, 2000
Mesalamine-induced lung toxicity has often been described. We report on a case of a patient who underwent mesalamine treatment, though in the absence of established criteria required for diagnosing Crohn's diseases (CD) or ulcerative colitis (UC).
Trisolini R., Luisetti M., Carrabino N., Dore R., BIAGI, FEDERICO, Pochetti P., Luinetti O.   +6 more
core  

Development and validation of an in vitro permeation test method for rectal mesalamine suppositories. [PDF]

Int J Pharm
Xie L, Kelchen M, Ghosh P, Niu M, Raney SG, Shen J.   +5 more
europepmc   +1 more source

Confirming the association of ulcerative colitis with interstitial lung disease: a retrospective analysis of comorbid disease, demographics, and healthcare utilization. [PDF]

Crohns Colitis 360
Parekh S, Burstiner LS, Romero K, Reddy A, Garcia GD, Vaezi A, Mirsaeidi M, Stemboroski L, Sulbaran M.   +8 more
europepmc   +1 more source

Eosinophilic pleural effusion due to mesalamine. Report of a rare occurrence

, 2000
: Mesalamine-induced lung toxicity has often been described. We report on a case of a patient who underwent mesalamine treatment, though in the absence of established criteria required for diagnosing Crohn's disease (CD) or ulcerative colitis (UC).
Trisolini, R
core   +1 more source

Refractory Hemorrhagic Radiation Proctitis Managed With Sequential Endoscopic, Topical, and Hyperbaric Oxygen Therapy. [PDF]

Cureus
Shakarchi T.
europepmc   +1 more source